Ipratropium bromide anhydrousProduct ingredient for Ipratropium

Ipratropium is a quaternary ammonium derivative of atropine⁴ that acts as an anticholinergic agent.¹ It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.⁴

Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and albuterol was approved in 1996.^12,11